Mangalam Drugs & Organics Past Earnings Performance
Past criteria checks 0/6
Mangalam Drugs & Organics's earnings have been declining at an average annual rate of -4.9%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 10% per year.
Key information
-4.9%
Earnings growth rate
-4.9%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 10.0% |
Return on equity | -12.8% |
Net Margin | -4.7% |
Next Earnings Update | 30 May 2024 |
Recent past performance updates
Recent updates
Little Excitement Around Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues As Shares Take 25% Pounding
Mar 28Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Shares Lagging The Industry But So Is The Business
Feb 07Estimating The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
Oct 20Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?
Mar 29These 4 Measures Indicate That Mangalam Drugs & Organics (NSE:MANGALAM) Is Using Debt Extensively
May 31A Look At The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
Apr 06We Think Mangalam Drugs & Organics (NSE:MANGALAM) Is Taking Some Risk With Its Debt
Jan 03Here's Why Mangalam Drugs & Organics (NSE:MANGALAM) Can Manage Its Debt Responsibly
May 23Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?
Jan 04Do Its Financials Have Any Role To Play In Driving Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Stock Up Recently?
Nov 12A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
Sep 20Does Mangalam Drugs & Organics's (NSE:MANGALAM) Statutory Profit Adequately Reflect Its Underlying Profit?
Aug 05We Think Mangalam Drugs & Organics (NSE:MANGALAM) Can Stay On Top Of Its Debt
Jul 01Revenue & Expenses BreakdownBeta
How Mangalam Drugs & Organics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 3,595 | -170 | 356 | 0 |
30 Sep 23 | 3,245 | -171 | 361 | 0 |
30 Jun 23 | 3,477 | -113 | 341 | 0 |
31 Mar 23 | 3,702 | 13 | 360 | 0 |
31 Dec 22 | 4,109 | 123 | 424 | 0 |
30 Sep 22 | 4,426 | 159 | 417 | 0 |
30 Jun 22 | 4,505 | 182 | 388 | 0 |
31 Mar 22 | 4,509 | 197 | 397 | 0 |
31 Dec 21 | 4,185 | 151 | 347 | 0 |
30 Sep 21 | 4,058 | 175 | 334 | 0 |
30 Jun 21 | 3,813 | 241 | 308 | 0 |
31 Mar 21 | 3,800 | 280 | 305 | 0 |
31 Dec 20 | 3,774 | 309 | 294 | 0 |
30 Sep 20 | 3,507 | 261 | 284 | 0 |
30 Jun 20 | 3,210 | 158 | 278 | 0 |
31 Mar 20 | 2,824 | 83 | 270 | 0 |
31 Dec 19 | 2,423 | -28 | 262 | 0 |
30 Sep 19 | 2,290 | -89 | 262 | 0 |
30 Jun 19 | 2,336 | -80 | 253 | 0 |
31 Mar 19 | 2,276 | -80 | 266 | 0 |
31 Dec 18 | 2,467 | 10 | 259 | 0 |
30 Sep 18 | 2,720 | 114 | 251 | 0 |
30 Jun 18 | 2,833 | 164 | 240 | 0 |
31 Mar 18 | 2,794 | 199 | 236 | 0 |
31 Dec 17 | 2,904 | 247 | 228 | 0 |
30 Sep 17 | 2,983 | 248 | 221 | 0 |
30 Jun 17 | 3,044 | 233 | 201 | 0 |
31 Mar 17 | 3,029 | 223 | 197 | 0 |
31 Dec 16 | 2,906 | 227 | 184 | 0 |
30 Sep 16 | 2,943 | 203 | 169 | 0 |
30 Jun 16 | 2,919 | 181 | 143 | 0 |
31 Mar 16 | 2,952 | 160 | 149 | 0 |
31 Dec 15 | 3,001 | 140 | 215 | 8 |
30 Sep 15 | 2,807 | 110 | 208 | 8 |
30 Jun 15 | 2,516 | 101 | 115 | 0 |
31 Mar 15 | 2,207 | 61 | 113 | 0 |
31 Dec 14 | 1,783 | 65 | 162 | 8 |
30 Sep 14 | 1,556 | 56 | 162 | 8 |
30 Jun 14 | 1,425 | 26 | 103 | 0 |
31 Mar 14 | 1,227 | -30 | 159 | 8 |
31 Dec 13 | 1,320 | -60 | 157 | 15 |
30 Sep 13 | 1,293 | -84 | 153 | 15 |
30 Jun 13 | 1,195 | -116 | 119 | 0 |
Quality Earnings: MANGALAM is currently unprofitable.
Growing Profit Margin: MANGALAM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MANGALAM is unprofitable, and losses have increased over the past 5 years at a rate of 4.9% per year.
Accelerating Growth: Unable to compare MANGALAM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MANGALAM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.3%).
Return on Equity
High ROE: MANGALAM has a negative Return on Equity (-12.83%), as it is currently unprofitable.